Paul J Thuluvath

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4490085/publications.pdf

Version: 2024-02-01

228 papers

13,245 citations

18482 62 h-index 24982 109 g-index

230 all docs 230 does citations

times ranked

230

12403 citing authors

#	Article	IF	CITATIONS
1	Gender Differences in Liver Transplantation Outcomes in Polycystic Liver Disease. Digestive Diseases and Sciences, 2022, 67, 3445-3454.	2.3	3
2	Reply to: "Universal definition and prognostication in acute-on- chronic liver failure – an unmet need!― Journal of Hepatology, 2022, 76, 242-243.	3.7	O
3	Impact of Hyponatremia on Morbidity, Mortality, and Resource Utilization in Portal Hypertensive Ascites: A Nationwide Analysis. Journal of Clinical and Experimental Hepatology, 2022, 12, 871-875.	0.9	4
4	Bariatric Surgery in NAFLD. Digestive Diseases and Sciences, 2022, 67, 408-422.	2.3	21
5	Prognosis of hospitalized patients with cirrhosis and acute kidney disease. Liver International, 2022, , .	3.9	2
6	Modified EASL-CLIF criteria that is easier to use and perform better to prognosticate acute-on-chronic liver failure. World Journal of Hepatology, 2022, 14, 420-428.	2.0	2
7	A model to predict inhospital mortality in patients with cirrhosis, ascites and hyponatremia. European Journal of Gastroenterology and Hepatology, 2022, Publish Ahead of Print, .	1.6	O
8	A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. Journal of Hepatology, 2022, 77, 353-364.	3.7	36
9	Antibody response after a booster dose of SARS-CoV-2 vaccine in liver transplant recipients and those with chronic liver diseases. Annals of Hepatology, 2022, 27, 100702.	1.5	18
10	Vaccination in Chronic Liver Disease: An Update. Journal of Clinical and Experimental Hepatology, 2022, 12, 937-947.	0.9	31
11	Increased Risk of ACLF and Inpatient Mortality in Hospitalized Patients with Cirrhosis and Hepatic Hydrothorax. Digestive Diseases and Sciences, 2021, 66, 3612-3618.	2.3	15
12	Progression of Stage 2 and 3 Acute Kidney Injury in Patients With Decompensated Cirrhosis and Ascites. Clinical Gastroenterology and Hepatology, 2021, 19, 1661-1669.e2.	4.4	14
13	How Good Are Controlled Attenuation Parameter Scores from Fibroscan to Assess Steatosis, NASH, and Fibrosis?. Digestive Diseases and Sciences, 2021, 66, 1297-1305.	2.3	8
14	Two-Dose Hepatitis B Vaccine (Heplisav-B) Results in Better Seroconversion Than Three-Dose Vaccine (Engerix-B) in Chronic Liver Disease. Digestive Diseases and Sciences, 2021, 66, 2101-2106.	2.3	26
15	Ubi pus, ibi evacua: Optimal Non-surgical Gallbladder Drainage Following Acute Cholecystitis. Digestive Diseases and Sciences, 2021, 66, 1383-1385.	2.3	O
16	Elevated Liver Biochemistries in Hospitalized Chinese Patients With Severe COVIDâ€19: Systematic Review and Metaâ€analysis. Hepatology, 2021, 73, 1521-1530.	7.3	39
17	Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. Journal of Hepatology, 2021, 74, 274-282.	3.7	34
18	Outcomes of status 1 liver transplantation for Buddâ€Chiari Syndrome with fulminant hepatic failure. American Journal of Transplantation, 2021, 21, 2211-2219.	4.7	5

#	Article	IF	Citations
19	REPLY:. Hepatology, 2021, 73, 2080-2081.	7.3	О
20	Acute liver failure in Budd–Chiari syndrome and a model to predict mortality. Hepatology International, 2021, 15, 146-154.	4.2	7
21	Gastrointestinal Manifestations of COVID-19., 2021, , 2299-2312.		O
22	Universal HCV Screening of Baby Boomers is Feasible, but It is Difficult. Journal of Clinical and Experimental Hepatology, 2021, 11, 661-667.	0.9	0
23	A Nationwide Analysis of Budd–Chiari Syndrome in the United States. Journal of Clinical and Experimental Hepatology, 2021, 11, 181-187.	0.9	11
24	Diabetic Hepatosclerosis in a Woman with Maturity-Onset Diabetes of the Young Type 3. Digestive Diseases and Sciences, 2021 , , 1 .	2.3	2
25	Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect. World Journal of Gastroenterology, 2021, 27, 1864-1882.	3.3	19
26	EASL-CLIF criteria outperform NACSELD criteria for diagnosis andÂprognostication in ACLF. Journal of Hepatology, 2021, 75, 1096-1103.	3.7	18
27	Admission Urinary and Serum Metabolites Predict Renal Outcomes in Hospitalized Patients With Cirrhosis. Hepatology, 2021, 74, 2699-2713.	7.3	27
28	An Introduction to Liver Disease in India. Clinical Liver Disease, 2021, 18, 105-107.	2.1	2
29	Effect of Sofosbuvir/Ledipasvir and Glecaprevir/Pibrentasvir on Serum Creatinine. Journal of Clinical and Experimental Hepatology, 2021, 12, 329-335.	0.9	0
30	Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases. Journal of Hepatology, 2021, 75, 1434-1439.	3.7	129
31	Liver biopsy in the real world—reporting, expert concordance and correlation with a pragmatic clinical diagnosis. Alimentary Pharmacology and Therapeutics, 2021, 54, 1472-1480.	3.7	10
32	Acute on Chronic Liver Failure: Factors Associated With Transplantation. Transplantation Direct, 2021, 7, e788.	1.6	8
33	Karnofsky Performance Status Following Liver Transplantation in Patients With Multiple Organ Failures and Probable Acute-on-Chronic Liver Failure. Clinical Gastroenterology and Hepatology, 2020, 18, 234-241.	4.4	21
34	Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox. Liver Transplantation, 2020, 26, 68-79.	2.4	26
35	Successful Treatment of Disseminated Hepatocellular Carcinoma After Liver Transplantation With Nivolumab. Journal of Clinical and Experimental Hepatology, 2020, 10, 185-187.	0.9	31
36	Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. Journal of Hepatology, 2020, 72, 885-895.	3.7	107

#	Article	IF	CITATIONS
37	Diabetes and Hepatocellular Carcinoma: Incidence Trends and Impact of Liver Disease Etiology. Journal of Clinical and Experimental Hepatology, 2020, 10, 296-303.	0.9	18
38	Multiple Regional Listing Increases Liver Transplant Rates for Those With Model for End-stage Liver Disease Score & 17. Transplantation, 2020, 104, 762-769.	1.0	5
39	What GI Physicians Need to Know During COVID-19 Pandemic. Digestive Diseases and Sciences, 2020, 66, 2865-2875.	2.3	7
40	Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis. Hepatology International, 2020, 14, 612-620.	4.2	97
41	Systematic review with metaâ€analysis: abnormalities in the international normalised ratio do not correlate with periprocedural bleeding events among patients with cirrhosis. Alimentary Pharmacology and Therapeutics, 2020, 52, 1298-1310.	3.7	19
42	Stage 1b acute kidney injury in cirrhosis is likely due to underlying chronic kidney disease and would be more appropriately re-classified as acute-on-chronic kidney disease. Journal of Hepatology, 2020, 73, S35-S36.	3.7	0
43	Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study. Journal of Hepatology, 2020, 73, S464-S465.	3.7	7
44	Hospitalization rates of Budd Chiari syndrome in the United States. Journal of Hepatology, 2020, 73, S543-S544.	3.7	1
45	Health care burden and in-hospital mortality of BCS in the United States between 1998 and 2016. Journal of Hepatology, 2020, 73, S544-S545.	3.7	0
46	Weight loss and change in alanine aminotransferase (ALT) among patients with non-alcoholic fatty liver disease (NAFLD) receiving standard care in real world clinical practice: TARGET-NASH. Journal of Hepatology, 2020, 73, S441.	3.7	0
47	If Hoofbeats are not From Horses, It Could be Zebras!! Isolated Hyper-alkaline Phosphatasemia. Journal of Clinical and Experimental Hepatology, 2020, 11, 619-622.	0.9	1
48	Hyponatremia in Cirrhosis: An Update. American Journal of Gastroenterology, 2020, 115, 1775-1785.	0.4	53
49	Are Gastrointestinal Symptoms Specific for Coronavirus 2019 Infection? A Prospective Case-Control Study From the United States. Gastroenterology, 2020, 159, 1161-1163.e2.	1.3	64
50	Underutilization of Hospice in Inpatients with Cirrhosis: The NACSELD Experience. Digestive Diseases and Sciences, 2020, 65, 2571-2579.	2.3	17
51	Acute-on-chronic liver failure in liver transplant candidates with non-alcoholic steatohepatitis. Translational Gastroenterology and Hepatology, 2020, 5, 38-38.	3.0	6
52	A Combination of N-Acetylcysteine and Prednisone Has No Benefit Over Prednisone Alone in Severe Alcoholic Hepatitis: A Retrospective Analysis. Digestive Diseases and Sciences, 2020, 65, 3726-3733.	2.3	12
53	Gastrointestinal and Liver Manifestations of COVID-19. Journal of Clinical and Experimental Hepatology, 2020, 10, 263-265.	0.9	85
54	Liver transplant waitlist removal, transplantation rates and post-transplant survival in Hispanics. PLoS ONE, 2020, 15, e0244744.	2.5	11

#	Article	IF	Citations
55	Liver injury in COVID-19: The hepatic aspect of the respiratory syndrome â€" what we know so far. World Journal of Hepatology, 2020, 12, 1182-1197.	2.0	18
56	496 A NEW ENDOLUMINAL THERAPEUTIC PLATFORM: RESULTS OF THE FIRST 519 INTERVENTIONS. Gastrointestinal Endoscopy, 2020, 91, AB46-AB47.	1.0	1
57	S0284â€∱Off-Label Use of the Multi-Target Stool DNA Test (Cologuardâ"¢) in Primary Care. American Journal of Gastroenterology, 2020, 115, S138-S139.	0.4	0
58	Liver transplant waitlist removal, transplantation rates and post-transplant survival in Hispanics., 2020, 15, e0244744.		0
59	Liver transplant waitlist removal, transplantation rates and post-transplant survival in Hispanics., 2020, 15, e0244744.		0
60	Liver transplant waitlist removal, transplantation rates and post-transplant survival in Hispanics. , 2020, 15, e0244744.		0
61	Liver transplant waitlist removal, transplantation rates and post-transplant survival in Hispanics., 2020, 15, e0244744.		0
62	Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field. Journal of Clinical and Experimental Hepatology, 2019, 9, 588-596.	0.9	43
63	Reversal of NASH fibrosis with pharmacotherapy. Hepatology International, 2019, 13, 534-545.	4.2	13
64	PS-170-A trend towards a lower patient survival is observed when either NAT+ve or NAT-ve donors with positive HCVAb are transplanted into HCV negative recipients. Journal of Hepatology, 2019, 70, e106-e107.	3.7	1
65	SAT-139-Predictive factors for the development of acute-on-chronic liver failure in a North American cohort of hospitalized patients with cirrhosis and decompensation. Journal of Hepatology, 2019, 70, e691-e692.	3.7	1
66	SAT-013-Potentially Preventable readmissions and complications in hospitalized patients with hepatic encephalopathy in a large multi-center cohort. Journal of Hepatology, 2019, 70, e630-e631.	3.7	0
67	Endoscopic en bloc removal of appendiceal polyp facilitatedÂbyÂtraction. VideoGIE, 2019, 4, 136-139.	0.7	6
68	Targets to improve quality of care for patients with hepatic encephalopathy: data from a multiâ€eentre cohort. Alimentary Pharmacology and Therapeutics, 2019, 49, 1518-1527.	3.7	40
69	Outcomes After Listing for Liver Transplant in Patients With Acuteâ€onâ€Chronic Liver Failure: The Multicenter North American Consortium for the Study of Endâ€Stage Liver Disease Experience. Liver Transplantation, 2019, 25, 571-579.	2.4	53
70	Outcomes in Patients With Cirrhosis on Primary Compared to Secondary Prophylaxis for Spontaneous Bacterial Peritonitis. American Journal of Gastroenterology, 2019, 114, 599-606.	0.4	17
71	Nosocomial Infections Are Frequent and Negatively Impact Outcomes in Hospitalized Patients With Cirrhosis. American Journal of Gastroenterology, 2019, 114, 1091-1100.	0.4	41
72	Waiting List Mortality and Transplant Rates for NASH Cirrhosis When Compared With Cryptogenic, Alcoholic, or AlH Cirrhosis. Transplantation, 2019, 103, 113-121.	1.0	28

#	Article	IF	CITATIONS
73	Reply to: "Type of organ failure and acute insult have important bearings in outcomes of liver transplantation: A pragmatic discourse― Journal of Hepatology, 2019, 70, 549-550.	3.7	1
74	Poor Survival After Retransplantation in NASH Cirrhosis. Transplantation, 2019, 103, 101-108.	1.0	10
75	NACSELD acuteâ€onâ€chronic liver failure (NACSELDâ€ACLF) score predicts 30â€day survival in hospitalized patients with cirrhosis. Hepatology, 2018, 67, 2367-2374.	7.3	197
76	Mental and physical health-related quality of life in patients with hepatitis C is related to baseline comorbidities and improves only marginally with hepatitis C cure. Clinical and Translational Gastroenterology, 2018, 9, e149.	2.5	5
77	High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis. Journal of Hepatology, 2018, 69, 293-300.	3.7	127
78	Longâ€ŧerm followâ€up of clinical trial patients treated for chronic HCV infection with daclatasvirâ€based regimens. Liver International, 2018, 38, 821-833.	3.9	20
79	Is cryptogenic cirrhosis different from NASH cirrhosis?. Journal of Hepatology, 2018, 68, 519-525.	3.7	49
80	Liver transplantation in patients with multiple organ failures: Feasibility and outcomes. Journal of Hepatology, 2018, 69, 1047-1056.	3.7	144
81	Reply to: "NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis― Journal of Hepatology, 2018, 69, 973-975.	3.7	4
82	Su1397 DIRECT COMPARISON OF ENDOSCOPIC ULTRASOUND AND COMPUTER TOMOGRAPH-GUIDED BIOPSY OF THE LIVER MASSES. Gastrointestinal Endoscopy, 2018, 87, AB340.	1.0	0
83	NEWSworthy but Not Ready for Prime Time. Clinical Gastroenterology and Hepatology, 2018, 16, 1566-1568.	4.4	O
84	Karnofsky performance status before and after liver transplantation predicts graft and patient survival. Journal of Hepatology, 2018, 69, 818-825.	3.7	68
85	Child-Turcotte-Pugh Class is Best at Stratifying Risk in Variceal Hemorrhage. Journal of Clinical Gastroenterology, 2017, 51, 446-453.	2.2	72
86	Sa1744 Visualization Balloon Facilitated Colonoscopy in 103 Consecutive Patients With Documented Difficult or Even Impossible Previous Colonoscopy. Gastrointestinal Endoscopy, 2017, 85, AB263.	1.0	1
87	A Karnofsky performance status–based score predicts death after hospital discharge in patients with cirrhosis. Hepatology, 2017, 65, 217-224.	7.3	74
88	Impact of Acute Kidney Injury on Mortality of Patients Hospitalized for Complications of Cirrhosis. Journal of Clinical and Experimental Hepatology, 2017, 7, 290-299.	0.9	6
89	Esophageal capsule endoscopy is not the optimal technique to determine the need for primary prophylaxis in patients with cirrhosis. Archives of Medical Science, 2016, 2, 365-371.	0.9	13
90	The 3â€month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. Hepatology, 2016, 64, 200-208.	7.3	189

#	Article	IF	Citations
91	Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic <scp>HCV</scp> genotype 1â€infected treatmentâ€naive patients. Liver International, 2016, 36, 189-197.	3.9	23
92	Driving Performance Among Patients with Cirrhosis Who Drove to Their Outpatient Hepatology Clinic Appointments. Journal of Clinical and Experimental Hepatology, 2016, 6, 3-9.	0.9	2
93	Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection. Annals of Internal Medicine, 2015, 163, 818-826.	3.9	96
94	Gender and ethnic differences in the post-liver transplant outcomes of patients with autoimmune hepatitis with acute liver failure at initial presentation: a case-control study. Archives of Medical Science, 2015, 6, 1227-1235.	0.9	8
95	Allâ€oral 12â€week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLYâ€3 phase III study. Hepatology, 2015, 61, 1127-1135.	7.3	598
96	Hyponatremia in cirrhosis: Pathophysiology and management. World Journal of Gastroenterology, 2015, 21, 3197-3205.	3.3	108
97	Endoscopic suturing closure of large iatrogenic colonic perforation. Gastrointestinal Endoscopy, 2015, 82, 754-755.	1.0	17
98	A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. Journal of Hepatology, 2015, 62, 1204-1206.	3.7	52
99	Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut, 2015, 64, 948-956.	12.1	101
100	Human bile contains MicroRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis. Hepatology, 2014, 60, 896-907.	7.3	187
101	Endoscopic suturing closure of large mucosal defects after endoscopic submucosal dissection is technically feasible, fast, and eliminates the need for hospitalization (with videos). Gastrointestinal Endoscopy, 2014, 79, 503-507.	1.0	179
102	Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. Journal of Hepatology, 2014, 61, 1220-1227.	3.7	25
103	Interventional Procedures in Hepatobiliary Diseases. Clinics in Liver Disease, 2014, 18, xiii-xiv.	2.1	0
104	Response:. Gastrointestinal Endoscopy, 2014, 80, 363-364.	1.0	2
105	Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection. New England Journal of Medicine, 2014, 370, 211-221.	27.0	1,065
106	Endoscopic Retrograde Cholangiography for Biliary Anastomotic Strictures After Liver Transplantation. Clinics in Liver Disease, 2014, 18, 913-926.	2.1	19
107	Sa1652 Diagnostic and Therapeutic Advantages of Carbon Dioxide Based Double-Balloon Enteroscopy for Management of Small Bowel Diseases: a 5-Year, Single-Center Experience. Gastrointestinal Endoscopy, 2013, 77, AB281.	1.0	1
108	Randomized Study of Asunaprevir plus Pegylated Interferon- $\hat{l}\pm$ and Ribavirin for Previously Untreated Genotype 1 Chronic Hepatitis C. Antiviral Therapy, 2013, 18, 885-893.	1.0	44

#	Article	IF	Citations
109	Successful closure of a chronic refractory gastrocutaneous fistula with a new endoscopic suturing device (with video). Gastrointestinal Endoscopy, 2012, 75, 688-690.	1.0	79
110	Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infectious Diseases, The, 2012, 12, 671-677.	9.1	139
111	Outcomes of liver transplantation for glycogen storage disease: a matchedâ€control study and a review of literature. Clinical Transplantation, 2012, 26, 432-436.	1.6	28
112	Endocrine Diseases and the Liver. Clinics in Liver Disease, 2011, 15, 55-67.	2.1	42
113	Evaluation of Liver Transplant Recipients. Journal of Clinical and Experimental Hepatology, 2011, 1, 199-203.	0.9	7
114	Utility and Safety of EUS-guided Portal Vein FNA. Gastroenterology and Hepatology, 2011, 7, 129-31.	0.1	3
115	Liver Transplantation in the United States, 1999-2008. American Journal of Transplantation, 2010, 10, 1003-1019.	4.7	421
116	Endoscopic Management of Biliary Complications After Liver Transplantation. Clinics in Liver Disease, 2010, 14, 359-371.	2.1	44
117	Successful removal of the proximally migrated pancreatic winged stent by using the SpyGlass visualization system. Gastrointestinal Endoscopy, 2010, 72, 454-455.	1.0	26
118	Management of Acute Hepatitis C. Clinics in Liver Disease, 2010, 14, 169-176.	2.1	57
119	Preface. Clinics in Liver Disease, 2010, 14, xiii-xiv.	2.1	0
120	Endoscopic Ultrasound and Fine-needle Aspiration for the Diagnosis of Hepatocellular Carcinoma. Clinics in Liver Disease, 2010, 14, 325-332.	2.1	21
121	Vascular Invasion is the Most Important Predictor of Survival in HCC, but How Do We Find It?. Journal of Clinical Gastroenterology, 2009, 43, 101-102.	2.2	24
122	MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology, 2009, 49, 1595-1601.	7.3	247
123	Liver failure as initial presentation of autoimmune hepatitis: Clinical characteristics, predictors of response to steroid therapy, and outcomes. Hepatology, 2009, 49, 1396-1397.	7.3	36
124	Survival after liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease and pre-model for end-stage liver disease eras and the independent impact of hepatitis C virus. Liver Transplantation, 2009, 15, 754-762.	2.4	24
125	Volumes of liver transplant and partial hepatectomy procedures are independently associated with lower postoperative mortality following resection for hepatocellular carcinoma. Liver Transplantation, 2009, 15, 776-781.	2.4	16
126	Insulin resistance and microalbuminuria are associated with microvascular disease in patients with cirrhosis. Liver Transplantation, 2009, 15, 1036-1042.	2.4	2

#	Article	IF	Citations
127	Morbid obesity and gross malnutrition are both poor predictors of outcomes after liver transplantation: What can we do about it?. Liver Transplantation, 2009, 15, 838-841.	2.4	10
128	A new alternative for a transjugular intrahepatic portosystemic shunt: EUS-guided creation of an intrahepatic portosystemic shunt (with video). Gastrointestinal Endoscopy, 2009, 69, 941-947.	1.0	79
129	Toward safer sedation in patients with cirrhosis: have we done enough?. Gastrointestinal Endoscopy, 2009, 70, 269-271.	1.0	18
130	Ultrasensitive Detection of KRAS2 Mutations in Bile and Serum from Patients with Biliary Tract Carcinoma Using LigAmp Technology. Journal of Molecular Diagnostics, 2009, 11, 583-589.	2.8	8
131	The Impact of Cirrhosis and Portal Hypertension on Mortality Following Colorectal Surgery: A Nationwide, Population-Based Study. Diseases of the Colon and Rectum, 2009, 52, 1367-1374.	1.3	83
132	18O Labeling for a Quantitative Proteomic Analysis of Glycoproteins in Hepatocellular Carcinoma. Clinical Proteomics, 2008, 4, 137-155.	2.1	18
133	Racial disparity in liver disease: Biological, cultural, or socioeconomic factors. Hepatology, 2008, 47, 1058-1066.	7.3	135
134	Hepatitis C is a predictor of acute liver injury among hospitalizations for acetaminophen overdose in the United States: A nationwide analysis. Hepatology, 2008, 48, 1336-1341.	7.3	92
135	A Quantitative Proteomic Approach for Identification of Potential Biomarkers in Hepatocellular Carcinoma. Journal of Proteome Research, 2008, 7, 4289-4298.	3.7	121
136	Acute hepatitis C. Lancet, The, 2008, 372, 321-332.	13.7	244
137	Race Is a Predictor of In-Hospital Mortality After Cholecystectomy, Especially in Those With Portal Hypertension. Clinical Gastroenterology and Hepatology, 2008, 6, 1146-1154.	4.4	14
138	Claudin-1 and its Potential Role in HCV Entry. Journal of Clinical Gastroenterology, 2008, 42, 3-4.	2.2	39
139	Prolonged Waiting Times for Liver Transplantation in Obese Patients. Annals of Surgery, 2008, 248, 863-870.	4.2	78
140	Correlation Between Hepatitis B Virus DNA Levels and Liver Histology. Journal of Clinical Gastroenterology, 2007, 41, 339-342.	2.2	1
141	Complementary and Alternative Medicine in Hepatology: Review of the Evidence of Efficacy. Clinical Gastroenterology and Hepatology, 2007, 5, 408-416.	4.4	7 3
142	Nationwide Increase in Hospitalizations and Hepatitis C Among Inpatients With Cirrhosis and Sequelae of Portal Hypertension. Clinical Gastroenterology and Hepatology, 2007, 5, 1092-1099.	4.4	81
143	Response:. Gastrointestinal Endoscopy, 2007, 65, 558.	1.0	0
144	EUS-guided FNA could be another important tool for the early diagnosis of hepatocellular carcinoma. Gastrointestinal Endoscopy, 2007, 66, 274-276.	1.0	14

#	Article	IF	CITATIONS
145	Endoscopic Retrograde Cholangiopancreatography (ERCP), But Not EGD Or Colonoscopy, Significantly Increases Portal Venous Pressure: Direct Portal Pressure Measurements Through EUS-Guided Catheterization. Gastrointestinal Endoscopy, 2007, 65, AB210.	1.0	0
146	Outcomes of patients with cirrhosis undergoing non-hepatic surgery: Risk assessment and management. World Journal of Gastroenterology, 2007, 13, 4056.	3. 3	118
147	Hepatorenal syndrome. World Journal of Gastroenterology, 2007, 13, 4046.	3.3	12
148	Racial disparities in the management of hospitalized patients with cirrhosis and complications of portal hypertension: A national study. Hepatology, 2007, 45, 1282-1289.	7.3	88
149	The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology, 2007, 46, 1828-1835.	7.3	127
150	Minimizing risk associated with elderly liver donors by matching to preferred recipients. Hepatology, 2007, 46, 1907-1918.	7.3	87
151	Trends in post–liver transplant survival in patients with hepatitis C between 1991 and 2001 in the united states. Liver Transplantation, 2007, 13, 719-724.	2.4	74
152	Twenty years of liver transplantation for Budd-Chiari syndrome: A national registry analysis. Liver Transplantation, 2007, 13, 1285-1294.	2.4	99
153	Lymphadenopathy, elevated liver function tests and weight loss in a 68-year-old man. Journal of Digestive Diseases, 2007, 8, 103-106.	1.5	3
154	Differences in characteristics of patients with and without known risk factors for hepatocellular carcinoma in the United States. World Journal of Gastroenterology, 2007, 13, 781.	3.3	9
155	Intrabiliary MR Imaging: Assessment of Biliary Obstruction with Use of an Intraluminal MR Receiver Coil. Journal of Vascular and Interventional Radiology, 2006, 17, 845-853.	0.5	12
156	Diagnosis of primary sclerosing cholangitis: a blinded comparative study using magnetic resonance cholangiography and endoscopic retrograde cholangiography. Gastrointestinal Endoscopy, 2006, 64, 219-223.	1.0	99
157	Perioperative and Postoperative Use of Immunosuppressive Agents in Liver Transplantation. International Anesthesiology Clinics, 2006, 44, 51-68.	0.8	6
158	Utility of Bile Duct Brushings for the Early Detection of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis. Journal of Clinical Gastroenterology, 2006, 40, 336-341.	2.2	24
159	Sirolimus Monotherapy Versus Sirolimus in Combination with Steroids and/or MMF for Immunosuppression After Liver Transplantation. Digestive Diseases and Sciences, 2006, 51, 1677-1684.	2.3	21
160	The Utility of TIPS in the Management of Budd-Chiari Syndrome. Annals of Surgery, 2005, 241, 978-983.	4.2	53
161	Short-term postliver transplant survival after the introduction of MELD scores for organ allocation in the United States. Liver International, 2005, 25, 536-541.	3.9	53
162	Reporting outcomes on living donor liver transplant. Liver Transplantation, 2005, 11, 245-245.	2.4	0

#	Article	IF	CITATIONS
163	When is diabetes mellitus a relative or absolute contraindication to liver transplantation? Liver Transplantation, 2005, 11 , S25-S29.	2.4	31
164	A Randomized Controlled Trial of ?-Blockers Versus Endoscopic Band Ligation for Primary Prophylaxis: A Large Sample Size is Required to Show a Difference in Bleeding Rates. Digestive Diseases and Sciences, 2005, 50, 407-410.	2.3	61
165	Diagnosis of Primary Sclerosing Cholangitis (PSC): A Blinded Comparative Study Using Magnetic Resonance Cholangiography (MRC) and Endoscopic Retrograde Cholangiography (ERC). Gastrointestinal Endoscopy, 2005, 61, AB213.	1.0	0
166	Transcatheter Arterial Chemoembolization in Unresectable Cholangiocarcinoma: Initial Experience in a Single Institution. Journal of Vascular and Interventional Radiology, 2005, 16, 353-361.	0.5	180
167	Role of endoscopy for primary prophylaxis of variceal bleeding. Techniques in Gastrointestinal Endoscopy, 2005, 7, 32-36.	0.3	0
168	Autonomic neuropathy may be associated with delayed orocaecal transit time in patients with cirrhosis. Autonomic Neuroscience: Basic and Clinical, 2005, 118, 135-139.	2.8	21
169	Hilar Cholangiocarcinoma: Staging with Intrabiliary MRI. American Journal of Roentgenology, 2004, 183, 1071-1074.	2.2	7
170	Reply:. American Journal of Gastroenterology, 2004, 99, 565-565.	0.4	0
171	A Proteomic Analysis of Human Bile. Molecular and Cellular Proteomics, 2004, 3, 715-728.	3.8	142
172	The V599E BRAF mutation is uncommon in biliary tract cancers. Modern Pathology, 2004, 17, 1386-1391.	5.5	40
173			
	Renal Insufficiency May Partly Explain Chronic Anemia in Patients Awaiting Liver Transplantation. Digestive Diseases and Sciences, 2004, 49, 629-632.	2.3	9
174	Patients with Autonomic Neuropathy Are More Likely to Develop Hepatic Encephalopathy. Digestive Diseases and Sciences, 2004, 49, 1584-1588.	2.3	9
174	Digestive Diseases and Sciences, 2004, 49, 629-632. Patients with Autonomic Neuropathy Are More Likely to Develop Hepatic Encephalopathy. Digestive		
	Digestive Diseases and Sciences, 2004, 49, 629-632. Patients with Autonomic Neuropathy Are More Likely to Develop Hepatic Encephalopathy. Digestive Diseases and Sciences, 2004, 49, 1584-1588.	2.3	10
175	Digestive Diseases and Sciences, 2004, 49, 629-632. Patients with Autonomic Neuropathy Are More Likely to Develop Hepatic Encephalopathy. Digestive Diseases and Sciences, 2004, 49, 1584-1588. Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer, 2004, 101, 1609-1615. Outcome of liver transplantation in adult recipients: Influence of neighborhood income, education,	2.3	10 95
175 176	Patients with Autonomic Neuropathy Are More Likely to Develop Hepatic Encephalopathy. Digestive Diseases and Sciences, 2004, 49, 1584-1588. Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer, 2004, 101, 1609-1615. Outcome of liver transplantation in adult recipients: Influence of neighborhood income, education, and insurance. Liver Transplantation, 2004, 10, 235-243. Graft and patient survival after adult live donor liver transplantation compared to a matched cohort	2.3 4.1 2.4	10 95 97
175 176 177	Patients with Autonomic Neuropathy Are More Likely to Develop Hepatic Encephalopathy. Digestive Diseases and Sciences, 2004, 49, 1584-1588. Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer, 2004, 101, 1609-1615. Outcome of liver transplantation in adult recipients: Influence of neighborhood income, education, and insurance. Liver Transplantation, 2004, 10, 235-243. Graft and patient survival after adult live donor liver transplantation compared to a matched cohort who received a deceased donor transplantation. Liver Transplantation, 2004, 10, 1263-1268. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with	2.3 4.1 2.4 2.4	10 95 97 143

#	Article	IF	Citations
181	TIPS for management of refractory ascites: response and survival are both unpredictable. Digestive Diseases and Sciences, 2003, 48, 542-550.	2.3	39
182	Prevalence of transaminase abnormalities in asymptomatic, healthy subjects participating in an executive health-screening program. Digestive Diseases and Sciences, 2003, 48, 797-801.	2.3	42
183	An endoscopic approach to biliary complications following orthotopic liver transplantation. Liver International, 2003, 23, 156-162.	3.9	164
184	Prolongation of QTc interval: relationship with etiology and severity of liver disease, mortality and liver transplantation. Liver International, 2003, 23, 243-248.	3.9	145
185	Pharmacological Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis. Drugs, 2003, 63, 1799-1812.	10.9	19
186	Primary Prophylaxis of Variceal Bleeding. Gastrointestinal Endoscopy, 2003, 58, 558-567.	1.0	21
187	Identification of Novel Cellular Targets in Biliary Tract Cancers Using Global Gene Expression Technology. American Journal of Pathology, 2003, 163, 217-229.	3.8	117
188	The village woman who winked and taught me the basics of medicine. Lancet, The, 2003, 362, 1658.	13.7	0
189	Relationship of The Model for End-Stage Liver Disease (Meld) Scale To Hepatic Encephalopathy, As Defined by Electroencephalography and Neuropsychometric Testing, and Ascites. American Journal of Gastroenterology, 2003, 98, 1395-1399.	0.4	81
190	Association between hepatitis C, diabetes mellitus, and race: a case-control study. American Journal of Gastroenterology, 2003, 98, 438-441.	0.4	85
191	The Outcome of Liver Transplantation in Patients With Hepatocellular Carcinoma in the United States Between 1988 and 2001: 5-Year Survival Has Improved Significantly With Time. Journal of Clinical Oncology, 2003, 21, 4329-4335.	1.6	235
192	Title is missing!. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 344-349.	1.3	65
193	Hospital experience and outcomes for esophageal variceal bleeding. International Journal for Quality in Health Care, 2003, 15, 139-146.	1.8	24
194	Chronic Pancreatitis. Journal of Clinical Gastroenterology, 2003, 36, 159-165.	2.2	65
195	Risk of Colorectal Adenoma in Liver Transplant Recipients Compared to Immunocompetent Control Population Undergoing Routine Screening Colonoscopy. Journal of Clinical Gastroenterology, 2003, 37, 72-73.	2.2	44
196	Portal Hypertensive Gastropathy. American Journal of Gastroenterology, 2002, 97, 2973-2978.	0.4	144
197	Mortality from hepatocellular and biliary cancers: changing epidemiological trends. American Journal of Gastroenterology, 2002, 97, 167-171.	0.4	25
198	The effect of insulin-dependent diabetes mellitus on outcome of liver transplantation. Transplantation, 2002, 74, 1007-1012.	1.0	108

#	Article	IF	CITATIONS
199	Liver transplantation for primary sclerosing cholangitis: screening for biliary malignancy and the role of preemptive transplantation. Current Opinion in Organ Transplantation, 2002, 7, 129-136.	1.6	7
200	Role of Liver Transplantation in the Management of Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2002, 13, S205-S210.	0.5	12
201	Effect of race on outcome of orthotopic liver transplantation: a cohort study. Lancet, The, 2002, 359, 287-293.	13.7	149
202	Screening for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2002, 13, S185-S190.	0.5	34
203	Outcome of orthotopic liver transplantation in patients with hepatitis C. Digestive Diseases and Sciences, 2002, 47, 450-455.	2.3	15
204	Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology, 2002, 35, 105-109.	7.3	367
205	Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology, 2002, 35, 1179-1185.	7.3	480
206	Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transplantation, 2002, 8, 708-713.	2.4	168
207	Socioeconomic status does not affect the outcome of liver transplantation. Liver Transplantation, 2002, 8, 1133-1137.	2.4	28
208	Accuracy and reliability of the endoscopic classification of portal hypertensive gastropathy. Gastrointestinal Endoscopy, 2002, 56, 675-680.	1.0	6
209	Prolonged QTc interval and its relationship to autonomic cardiovascular reflexes in patients with cirrhosis. Journal of Hepatology, 2001, 35, 733-738.	3.7	62
210	Vaccination, Screening for Malignancy, and Health Maintenance of the Liver Transplant Recipient. Journal of Clinical Gastroenterology, 2001, 32, 148-150.	2.2	16
211	Features of Recurrent Primary Sclerosing Cholangitis in Two Consecutive Liver Allografts After Liver Transplantation. Journal of Clinical Gastroenterology, 2001, 32, 151-154.	2.2	16
212	HUMAN MONOCYTIC EHRLICHIOSIS: AN EMERGING PATHOGEN IN TRANSPLANTATION. Transplantation, 2001, 71, 1678-1680.	1.0	33
213	Autonomic dysfunction and cholelithiasis in patients with cirrhosis. Digestive Diseases and Sciences, 2001, 46, 495-498.	2.3	16
214	Outcome of liver transplantation in patients with diabetes mellitus: A case-control study. Hepatology, 2001, 34, 889-895.	7.3	132
215	Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol. Liver Transplantation, 2001, 7, 745-749.	2.4	70
216	Spontaneous Bacterial Peritonitis—in-Hospital Mortality, Predictors of Survival, and Health Care Costs From 1988 To 1998. American Journal of Gastroenterology, 2001, 96, 1232-1236.	0.4	129

#	Article	lF	CITATION
217	Recurrent, Progressive Giant Cell Hepatitis in Two Consecutive Liver Allografts in a Middle-aged Woman. Journal of Clinical Gastroenterology, 2001, 32, 454-456.	2.2	27
218	Heart rate variability as a predictor of autonomic dysfunction in patients awaiting liver transplantation. Digestive Diseases and Sciences, 2000, 45, 340-344.	2.3	41
219	Prevalence of Obesity and Diabetes in Patients With Cryptogenic Cirrhosis: A Case-Control Study. Hepatology, 2000, 32, 689-692.	7.3	476
220	Autonomic and peripheral (sensorimotor) neuropathy in chronic liver disease: A clinical and electrophysiologic study. Hepatology, 1999, 29, 1698-1703.	7.3	89
221	Cognitive impairment in alcoholic and nonalcoholic cirrhotic patients. Hepatology, 1999, 30, 1363-1367.	7.3	35
222	A prospective, randomized, double-blind trial evaluating the efficacy of ursodeoxycholic acid in prevention of liver transplant rejection. Liver Transplantation, 1998, 4, 276-279.	1.8	15
223	Assessment of nutritional status via anthropometry. Nutrition, 1997, 13, 714-717.	2.4	7
224	Increased signals seen in globus pallidus in T1-weighted magnetic resonance imaging in cirrhotics are not suggestive of chronic hepatic encephalopathy. Hepatology, 1995, 21, 440-442.	7.3	54
225	Metabolic basis for high paracetamol dosage without hepatic injury: a case study. Human and Experimental Toxicology, 1995, 14, 8-12.	2.2	21
226	Effects of Helicobacter pylori Infection and Gastritis on Gastric Alcohol Dehydrogenase Activity. Alcoholism: Clinical and Experimental Research, 1994, 18, 795-798.	2.4	35
227	Treatment of high-risk patients with symptomatic cholelithiasis by endoscopic gallbladder stenting. Gastrointestinal Endoscopy, 1994, 40, 608-610.	1.0	36
228	Liver ultrasound in cirrhosis is inadequate for hepatocellular carcinoma surveillance compared to magnetic resonance imaging. Liver Cancer International, 0, , .	1.3	0